Xeris Biopharma develops ready-to-use injectable therapies using proprietary formulation technologies that keep traditionally unstable drugs in stable liquid form. Its portfolio includes Gvoke for severe hypoglycemia and Recorlev for endogenous Cushing’s syndrome. The company focuses on endocrinology and related specialty markets where simpler administration can matter for patients and caregivers.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 71.5 | — | -1.9 | — |
| Q3 2025 | 74.4 | — | 0.6 | — |
| Q4 2025 | 85.8 | — | 11.1 | — |
| Q1 2026 | 83.1 | — | 2.2 | — |
| Q2 2026 | 92.1 | 28.7% | -31.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: German American Bancorp, Inc. (GABC), Agios Pharmaceuticals, Inc. (AGIO), Karooooo Ltd. (KARO), Recursion Pharmaceuticals, Inc. (RXRX), Novavax, Inc. (NVAX), Cimpress plc (CMPR)